drugset / Trial / NCT00477607
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
Phase 2/3
Completed
39 enrolled
US Department of Veterans Affairs
Oregon Health and Science University · collab
RandomizedParallel-groupTriple-blindSupportive care
Summary
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin.
Timeline
- Start
- 2007-10
- Primary completion
- 2011-03
- Completion
- 2011-06
Outcome
Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)
registry analysis (superiority or other test); Arm 1 vs Arm 2; p = 0.89; Odds Ratio (OR) 2 (95% CI 0.4 to 11.4); Fisher Exact NCT00477607 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | alpha-lipoic acid | Small molecule | 1200 mg | Oral |